- Home
- PLUG vs KNSA Comparison
PLUG vs KNSA Comparison
Compare PLUG & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | KNSA |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PLUG | KNSA |
|---|---|---|
| Price | $2.48 | $42.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $2.10 | ★ $52.33 |
| AVG Volume (30 Days) | ★ 96.8M | 601.6K |
| Earning Date | 03-02-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $676,169,000.00 | $597,973,000.00 |
| Revenue This Year | $20.13 | $62.63 |
| Revenue Next Year | $23.87 | $31.78 |
| P/E Ratio | ★ N/A | $90.40 |
| Revenue Growth | 2.53 | ★ 55.68 |
| 52 Week Low | $0.69 | $18.12 |
| 52 Week High | $4.58 | $44.42 |
Technical Indicators
Market Signals| Indicator | PLUG | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 55.24 |
| Support Level | $2.12 | $37.02 |
| Resistance Level | $2.42 | $39.74 |
| Average True Range (ATR) | 0.21 | 2.07 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 65.04 | 81.78 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.